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Pediatric neuro-oncologists are familiar with the challenge that their potentially 
curative treatments may come at a high prize because they may allow survival, but 
not without developmental delays and persistent neuropsychological sequelae in a 
significant proportion of their patients. The view that the radiological determination of 
response or stable disease is a sufficient parameter to ascertain that “my patient is 
doing well”, has long been challenged in adult Neuro-Oncology in the primary CNS 
lymphoma field as well as in the cohorts of brain metastasis patients treated with 
whole brain radiotherapy. In contrast, neurocognitive function in malignant glioma 
patients has traditionally been assumed to roughly reflect the status of tumor control. 
This has often been true because the treatment modalities administered to these 
patients have been less aggressive, in part because of their non-curative nature, and 
because the lengths of survival have often been too short to allow to experience 
long-term adverse effects of treatment. 
Neurocognitive function has now become an interesting endpoint from another angle. 
The introduction of bevacizumab, an antibody to the vascular endothelial growth 
factor (VEGF), and other VEGF targeting agents into the repertoire of medical 
options for malignant glioma patients has challenged the view that our current 
imaging criteria are sufficient to estimate the benefit derived from all new agents, 
irrespective of their mode of action (1). In fact, the assessment of neurocognitive 
function may now become an important, more-than-surrogate marker to determine 
whether an apparently successful treatment as assessed by neuroimaging truly 
translates into a clinical benefit for the patient. Fortunately, this issue was recognized 
when the BRAIN trial, that assessed the safety and efficacy of bevacizumab with and 
without irinotecan in patients with recurrent glioblastoma, was designed. Wefel and 
colleagues (2) now report the development of neurocognitive function in the first 24 
weeks after study entry in a major proportion of the participants of the BRAIN trial. 
They find that most patients with at least stable disease at 24 weeks had also stable 
or improved neurocognitive function whereas progressing patients commonly had 
cognitive decline. In the absence of the demonstration of a survival benefit for 
bevacizumab in recurrent glioblastoma, because no study with an appropriate 
bevacizumab-free control arm was performed, these data are reassuring because 
they indicate that the responses seen by neuroimaging were most often associated 
with the preservation or improvement of neurocognitive function. The most interesting 
subgroup of patients is the one of approximately 30% which exhibited some 
neurocognitive decline in the absence of documented tumor progression. Although 
no correlative analyses with the MRI patterns were reported, it is tempting to assume 
that patients with non-enhancing diffuse progression, which escapes response 
criteria heavily based on contrast-enhanced imaging, may have been in that 
subgroup. On the other hand, cognitive decline preceding MRI-documented 
progression has also been noted in the pre-bevacizumab era (3). 
Neurocognitive function remains a difficult endpoint to assess and interpret, given the 
multitude of confounding factors such as comedication, notably with antidepressant 
drugs, and psychiatric disorders, notably depression. Nevertheless, efforts such as 
the present analysis of the BRAIN trial are necessary and welcome to better estimate 
the clinical impact of new treatments administered in an eventually palliative setting. 
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